Artificial ribonucleases: Efficient and specific in vitro cleavage of human c-raf-1 RNA

Bioconjugate Chemistry

Volumn 13, Issue 5, 2002, Pages 945-951

  Canaple, Laurence ^a   Hüsken, Dieter ^b   Hall, Jonathan ^b   Häner, Robert ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFFICIENCY; EUROPIUM COMPOUNDS; OLIGONUCLEOTIDES;

CLEAVAGE EFFICIENCY; CLEAVAGE SITES; EUROPIUM COMPLEX; EXTENSION ANALYSIS; IN-VITRO; MODIFIED OLIGONUCLEOTIDES; PRIMER EXTENSION; SEQUENCE-SPECIFIC MANNER; SPECIFIC CLEAVAGES; TARGET REGIONS;

RNA;

EUROPIUM; OLIGONUCLEOTIDE; RAF PROTEIN; RIBONUCLEASE; RNA;

ARTICLE; CHEMISTRY; DRUG EFFECT; ENZYME SPECIFICITY; GENETICS; HUMAN; HYDROLYSIS; METABOLISM; MOLECULAR MIMICRY; SYNTHESIS;

EUROPIUM; HUMANS; HYDROLYSIS; MOLECULAR MIMICRY; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-RAF; RIBONUCLEASES; RNA; SUBSTRATE SPECIFICITY;

EID: 0036738528     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0200024     Document Type: Article

References (27)

1. Agrawal, S., and Zhao, Q. (1998) Antisense therapeutics. Curr. Opin. Chem. Biol. 2 (4), 519-528.
2. Bos, J. L. (1989) ras oncogenes in human cancer, a review. Cancer Res. 49 (17), 4682-4689.
3. Baker, B. F., Lot, S. S., Kringel, J., Cheng-Flournoy, S., Villiet, P., Sasmor, H. M., Siwkowski, A. M., Chappell, L. L., and Morrow, J. R. (1999) Oligonucleotide-europium complex conjugate designed to cleave the 5′ cap structure of the ICAM-1 transcript potentiates antisense activity in cells. Nucleic Acids Res. 27 (6), 1547-1551.
4. Baker, B. F., Condon, T. P., Koller, E., McKay, R. A., Siwkowski, A. M., Vickers, T. A., and Monia, B. P. (2001) Discovery and analysis of antisense oligonucleotide activity in cell culture. Methods 23 (2), 191-198.
5. Cho-Chung, Y. S. (1999) Antisense oligonucleotide inhibition of serine/threonine kinases, an innovative approach to cancer treatment. Pharmacol. Ther. 82 (2-3), 437-449.
6. Crooke, S. T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489 (1), 31-44.
7. Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., and Levin, A. A. (2001a) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogues in rats. J. Pharmacol. Exp. Ther. 296 (3), 890-897.
8. Geary, R. S., Khatsenko, O., Bunker, K., Crooke, R., Moore, M., Burckin, T., Truong, L., Sasmor, H., and Levin, A. A. (2001b) Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296 (3), 898-904.
9. Hagemann, C., and Rapp, U. R. (1999) Isotype-specific functions of Raf kinases. Exp. Cell. Res. 253 (1), 34-46.
10. Hall, J., Hüsken, D., Pieles, U., Moser, H. E., and Häner, R. (1994) Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides. Chem. Biol. 1 (3), 185-190.
11. Hall, J., Hüsken, D., and Häner, R. (1996) Towards artificial ribonucleases, the sequence-specifc cleavage of RNA in a duplex. Nucleic Acids Res. 24 (18), 3522-3526.
12. Häner, R., and Hall, J. (1997) The sequence-specific cleavage of RNA by artificial chemical ribonucleases. Antisense Nucleic Acid Drug Dev. 7 (4), 423-430.
13. Henry, S., Stecker, K., Brooks, D., Monteith, D., Conklin, B., and Bennett, C. F. (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292 (2), 468-479.
14. Hüsken, D., Goodall, G., Blommers, M. J., Jahnke, W., Hall, J., Häner, R., and Moser, H. E. (1996) Creating RNA bulges, cleavage of RNA in RNA/DNA duplexes by metal ion catalysis. Biochemistry 35 (51), 16591-16600.
15. Jen, K. Y., and Gewirtz, A. M. (2000) Suppression of gene expression by targeted disruption of messenger RNA, available options and current strategies. Stem Cells 18 (5), 307-319.
16. Kolasa, K. A., Morrow, J. R., and Sharma, A. P. (1993) Trivalent lanthanide ions do not cleave RNA in DNA-RNA hybrids. Inorg. Chem. 32, 3983-3984.
17. Lima, W. F., Monia, B. P., Ecker, D. J., and Freier, S. M. (1992) Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31 (48), 12055-12061.
18. Magda, D., Miller, R. A., Wright, M., Rao, J., Sessler, J. L., Iverson, B. L., and Sansom, P. I. (1994) Site-specific hydrolysis of RNA by europium (III) texaphyrin conjugated to a synthetic oligodeoxyribonucleotide. J. Am. Chem. Soc. 116, 6439-6440.
19. Marshall, M. (1995) Interactions between Ras and Raf, key regulatory proteins in cellular transformation. Mol. Reprod. Dev. 42 (4), 493-499.
20. Matsumura, K., Endo, M., and Komiyama, M. (1994) Lanthanide complex-oligo-DNA hybrid for sequence-selective hydrolysis of RNA. J. Chem. Soc., Chem. Commun. 2019-2020.
21. Robinson, M. J., and Cobb, M. H. (1997) Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9 (2), 180-186.
22. Stanton, V. P. Jr., and Cooper, G. M. (1987) Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol. Cell. Biol. 7 (3), 1171-1179.
23. Trawick, B. N., Daniher, A. T., and Bashkin, J. K. (1998) Inorganic Mimics of Ribonucleases and Ribozymes, From Random Cleavage to Sequence-Specific Chemistry to Catalytic Antisense Drugs. Chem. Rev. 98, 939-960.
24. Storm, S. M., and Rapp, U. R. (1993) Oncogene activation, c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol. Lett. 67 (1-3), 201-210.
25. Verma, S., and Eckstein, F. (1998) Modified oligonucleotides, synthesis and strategy for users. Annu. Rev. Biochem. 67, 99-134.
26. Zellweger, T., Miyake, H., Cooper, S., Chi, K., Conklin, B. S, Monia, B. P., and Gleave, M. E. (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298 (3), 934-940.
27. Zuker, M. (1989) Computer prediction of RNA structure. Methods Enzymol. 180, 262-288.